Peculiarities of clinical manifestations of Helicobacter pylori infection in healthcare professionals


DOI: https://dx.doi.org/10.18565/therapy.2024.5.39-48

Luzina E.V., Lazebnik L.B., Lareva N.V., Zhilina A.A., Moskvitina A.A.

1) Chita State Medical Academy of the Ministry of Healthcare of Russia; 2) Russian University of Medicine of the Ministry of Healthcare of Russia, Moscow; 3) Multidisciplinary Medical Center “Medlux”, Chita
Abstract. A significant correlation is shown in the number of studies between H. pylori infection and occupation of people. Higher H. pylori positivity was also found among medical professionals.
The aim: to analyze the characteristics of the clinical picture, personal and family history data in H. pylori-positive subjects, depending on their involvement in medical activities, and to identify some higher risk factors for the presence of H. pylori infection.
Material and methods. 182 individuals were examined, including 107 medical and 75 non-medical workers. H. pylori was diagnosed when antigen was detected in the stool. The presence and frequency of any symptoms, existing gastrointestinal tract (GIT) pathology, hereditary history of peptic ulcer (PU) and gastric cancer (GC) were assessed.
Results. H. pylori was detected in 128 individuals, including 72 medical and 56 non-medical workers. The level of H. pylori infection was 2.61 times higher among subjects with upper gastrointestinal symptoms (p = 0.008), 3.83 times higher among subjects with a personal history of erosive and ulcerative diseases (p = 0.012), 8.12 times higher – with a family history of gastric cancer (p = 0.019). The structure of symptoms was dominated by pain in epigastric area (p = 0.005), heartburn (p = 0.022) and belching (p = 0.033). Medical professionals were 3.83 times more likely to have a family history of GU, regardless of H. pylori status (p = 0.007), and H. pylori infection was positively associated with a family history of gastric cancer (odds ratio 6.8; 95% confidence interval: 0.85–54.59, p = 0.041).
Conclusion. High risk of H. pylori infection is associated with individuals having upper gastrointestinal symptoms (such as epigastric pain, heartburn and belching), a personal history of erosive and ulcerative lesions and a family history of gastric cancer, regardless of professional background. Medical professionals were more likely to have a hereditary history of ulcers, regardless of H. pylori status, and gastric cancer with H. pylori positivity.
Keywords: healthcare professionals, clinical manifestations, Helicobacter pylori, risk factors
Read entire article

Literature

1. Malfertheiner P., Camargo M.C., El-Omar E. et al. Helicobacter pylori infection. Nat Rev Dis Primers. 2023; 9(1): 19.


https://doi.org/10.1038/s41572-023-00431-8. PMID: 37081005.


2. Hooi J.K.Y., Lai W.Y., Ng W.K. et al. Global prevalence of Helicobacter pylori infection: Systematic review and meta-analysis. Gastroenterology. 2017; 153(2): 420–29.


https://doi.org/10.1053/j.gastro.2017.04.022. PMID: 28456631.


3. Kayali S., Manfredi M., Gaiani F. et al. Helicobacter pylori, transmission routes and recurrence of infection: State of the art. Acta Biomed. 2018; 89(8-S): 72–76.


https://doi.org/10.23750/abm.v89i8-S.7947. PMID: 30561421. PMCID: PMC6502203.


4. Шульгина Е.М., Караулова Л.В., Симонова Ж.Г. Оценка вероятности инфицированности Helicobacter pylori у больных с гастродуоденальной патологией в зависимости от факторов риска с использованием модели логит-регрессии. Вятский медицинский вестник. 2019; (3): 50–57. (Shulgina E.M., Karaulova L.V., Simonova Zh.G. Assessing probability of Helicobacter pylori infection in patients with gastro-duodenal pathology (GDP) in association with risk factors and using logit-regression model. Vyatskiy meditsinskiy vestnik = Medical Newsletter of Vyatka. 2019; (3): 50–57 (In Russ.)).


https://doi.org/10.24411/2220-7880-2019-1001. EDN: VIJTIR.


5. Chen R.-X., Zhang D.-Y., Zhang X. et al. A survey on Helicobacter pylori infection rate in Hainan Province and analysis of related risk factors. BMC Gastroenterol. 2023; 23(1): 338.


https://doi.org/10.1186/s12876-023-02973-3. PMID: 37777740. PMCID: PMC10544117.


6. Kheyre H., Morais S., Ferro A. et al. The occupational risk of Helicobacter pylori infection: A systematic review. Int Arch Occup Environ Health. 2018; 91(6): 657–74.


https://doi.org/10.1007/s00420-018-1315-6. PMID: 29845564.


7. Toosi S.M.V., Yaghobi M., Pour R.A.M. Prevalence of Helicobacter pylori infection in patients with dyspepsia in north of Iran. Middle East J Dig Dis. 2021; 13(3): 230–36.


https://doi.org/10.34172/mejdd.2021.230. PMID: 36606221. PMCID: PMC9489463.


8. Khoder Gh., Mina S., Mahmoud I. et al. Helicobacter pylori infection in Tripoli, North Lebanon: Assessment and risk factors. Biology (Basel). 2021; 10(7): 599. https://doi.org/10.3390/biology10070599. PMID: 34203570. PMCID: PMC8301113.


9. Loor A., Dumitrascu D.-L., Surdea-Blaga T. et al. Helicobacter pylori infection and positive Rome IV criteria for functional dyspepsia in Romanian medical students. J Med Life. 2021; 14(4): 492–97.


https://doi.org/10.25122/jml-2021-0163. PMID: 34621372. PMCID: PMC8485373.


10. Плавник Р.Г., Бакулина Н.В., Мареева Д.В., Бордин Д.С. Эпидемиология Helicobacter pylori: клинико-лабораторные параллели. Эффективная фармакотерапия. 2019; 15(36): 16–21. (Plavnik R.G., Bakulina N.V., Mareyeva D.V., Bordin D.S. Helicobacter pylori epidemiology: Clinical and laboratory parallels. Effektivnaya farmakoterapiya = Effective Pharmacotherapy. 2019; 15(36): 16–21 (In Russ.)).


https://doi.org/10.33978/2307-3586-2019-15-36-16-20. EDN: YGGDCT.


11. Бордин Д.С., Плавник Р.Г., Невмержицкий В.И. с соавт. Распространенность Helicobacter pylori среди медицинских работников Москвы и Казани по данным 13С-уреазного дыхательного теста. Альманах клинической медицины. 2018; 46(1): 40–49. (Bordin D.S., Plavnik R.G., Nevmerzhitskiy V.I. et al. Prevalence of Helicobacter pylori among medical workers in Moscow and Kazan according to 13С-urease breath test. Al’manakh klinicheskoy meditsiny = Almanac of Clinical Medicine. 2018; 46(1): 40–49 (In Russ.)).


https://doi.org/10.18786/2072-0505-2018-46-1-40-49. EDN: YVSHHC.


12. Zhang Ch.-L., Geng Ch.-H., Yang Zh.-W. et al. Changes in patients’ symptoms and gastric emptying after Helicobacter pylori treatment. World J Gastroenterol. 2016; 22(18): 4585–93.


https://doi.org/10.3748/wjg.v22.i18.4585. PMID: 27182168. PMCID: PMC4858640.


13. Du L.-J., Chen B.-R., Kim J.J. et al. Helicobacter pylori eradication therapy for functional dyspepsia: Systematic review and meta-analysis. World J Gastroenterol. 2016; 22(12): 3486–95.


https://doi.org/10.3748/wjg.v22.i12.3486. PMID: 27022230. PMCID: PMC4806206.


14. Ali A., AlHussaini Kh.I. Helicobacter pylori: A contemporary perspective on pathogenesis, diagnosis and treatment strategies. Microorganisms. 2024; 12(1): 222.


https://doi.org/10.3390/microorganisms12010222. PMID: 38276207. PMCID: PMC10818838.


15. Shahinyan T., Amaryan G., Tadevosyan A., Braegger Ch. Clinical, endoscopic, and histological characteristics of Helicobacter pylori positive and negative Armenian children with recurrent abdominal pain and/or dyspepsia. Georgian Med News. 2022; (324): 71–78. PMID: 35417865.


16. Oztekin M., Yılmaz B., Agagunduz D., Capasso R. Overview of Helicobacter pylori infection: Clinical features, treatment, and nutritional aspects. Diseases. 2021; 9(4): 66.


https://doi.org/10.3390/diseases9040066. PMID: 34698140. PMCID: PMC8544542.


17. Leja M., Grinberga-Derica I., Bilgilier C., Steininger Ch. Review: Epidemiology of Helicobacter pylori infection. Helicobacter. 2019: 24 Suppl 1: e12635.


https://doi.org/10.1111/hel.12635. PMID: 31486242.


18. Niknam R., Lankarani K.B., Moghadami M. et al. The association between Helicobacter pylori infection and erosive gastroesophageal reflux disease; A cross-sectional study. BMC Infect Dis. 2022; 22(1): 267.


https://doi.org/10.1186/s12879-022-07278-6. PMID: 35305563. PMCID: PMC8934462.


19. Zhang F., Pu K., Wu Zh. et al. Prevalence and associated risk factors of Helicobacter pylori infection in the Wuwei cohort of north-western China. Trop Med Int Health. 2021; 26(3): 290–300.


https://doi.org/10.1111/tmi.13517. PMID: 33159827.


20. Бордин Д.С., Ливзан М.А., Осипенко М.Ф. с соавт. Ключевые положения консенсуса Маастрихт VI. Экспериментальная и клиническая гастроэнтерология. 2022; (9): 5–21. (Bordin D.S., Livzan M.A., Osipenko M.F. et al. The key statements of the Maastricht VI consensus. Eksperimental’naya i klinicheskaya gastroenterologiya = Experimental and Clinical Gastroenterology. 2022; (9): 5–21 (In Russ.)).


https://doi.org/10.31146/1682-8658-ecg-205-9-5-21. EDN: KQDIHJ.


21. Sugano K. Effect of Helicobacter pylori eradication on the incidence of gastric cancer: A systematic review and meta-analysis. Gastric Cancer. 2019; 22(3): 435–45.


https://doi.org/10.1007/s10120-018-0876-0. PMID: 30206731.


22. Muzaheed. Helicobacter pylori oncogenicity: Mechanism, prevention, and risk factors. ScientificWorldJournal. 2020; 2020: 3018326.


https://doi.org/10.1155/2020/3018326. PMID: 32765194. PMCID: PMC7374235.


23. Lin H-Y., Weng Sh-F., Lin H-J. et al. Peptic ulcer disease in healthcare workers: A nationwide population-based cohort study. PLoS One. 2015; 10(8): e0135456.


https://doi.org/10.1371/journal.pone.0135456. PMID: 26301861. PMCID: PMC4547755.


24. Рашина О.В., Чурносов М.И. Гены-кандидаты язвенной болезни. Экспериментальная и клиническая гастроэнтерология. 2021; (2): 52–57. (Rashina O.V., Churnosov M.I. Peptic ulcer candidate genes. Eksperimental’naya i klinicheskaya gastroenterologiya = Experimental and Clinical Gastroenterology. 2021; (2): 52–57 (In Russ.)).


https://doi.org/10.31146/1682-8658-ecg-186-2-52-57. EDN: XIBWVJ.


25. Бордин Д.С., Войнован И.Н., Колбасников С.В., Эмбутниекс Ю.В. Методы диагностики инфекции Helicobacter pylori в клинической практике. Терапевтический архив. 2018; 90(12): 133–139. (Bordin D.S., Voynovan I.N., Kolbasnikov S.V., Embutnieks Yu.V. Diagnosis of Helicobacter pylori infection in clinical practice. Terapevticheskiy arkhiv = Therapeutic Archive. 2018; 90(12): 133–139 (In Russ.)).


https://doi.org/10.26442/00403660.2018.12.000020. EDN: YROFYT.


26. Заболеваемость населения Забайкальского края за 2007–2008 гг. (статистические материалы). Чита. 2009: 146 с. (Morbidity of the population of the Trans-Baikal Region in 2007–2008 (statistical materials). Chita. 2009: 146 pp. (In Russ.)).


27. Заболеваемость населения Забайкальского края за 2017–2018 гг. (статистические материалы). Чита. 2019: 152 с. (Morbidity of the population of the Trans-Baikal Region in 2017–2018 (statistical materials). Chita. 2019: 152 pp. (In Russ.)).


28. Клинические рекомендации. Гастрит и дуоденит. Российская гастроэнтерологическая ассоциация, ассоциация «Эндоскопическое общество „РЭндО“». Рубрикатор клинических рекомендаций Минздрава России. 2021. ID: 708. Доступ: https://cr.minzdrav.gov.ru/recomend/708_1 (дата обращения – 24.06.2024). (Clinical guidelines. Gastritis and duodenitis. Russian Gastroenterological Association, Association “REndO Endoscopic Society”. Rubricator of clinical guidelines of the Ministry of Healthcare of Russia. 2023. ID: 708. URL: https://cr.minzdrav.gov.ru/recomend/708_1 (date of access – 24.06.2024) (In Russ.)).


29. Маев И.В., Лазебник Л.Б., Бордин Д.С. с соавт. Резолюция Экспертного совета «Необследованная диспепсия: краткосрочная и долгосрочная стратегии ведения пациента». Эффективная фармакотерапия. 2023; 19(8): 16–24. (Maev I.V., Lazebnik L.B., Bordin D.S. et al. Resolution of the expert council “Unexplored dyspepsia: Short-term and long-term patient management strategies”. Effektivnaya farmakoterapiya = Effective Pharmacotherapy. 2023; 19(8): 16–24 (In Russ.)).


https://doi.org/10.33978/2307-3586-2023-19-8-16-24. EDN: KJNOBN.


30. Ивашкин В.Т., Лапина Т.Л., Маев И.В. с соавт. Клинические рекомендации Российской гастроэнтерологической ассоциации, Научного сообщества по содействию клиническому изучению микробиома человека, Российского общества профилактики неинфекционных заболеваний, Межрегиональной ассоциации по клинической микробиологии и антимикробной химиотерапии по диагностике и лечению H. pylori у взрослых. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2022; 32(6): 72–93. (Ivashkin V.T., Lapina T.L., Maev I.V. et al. Clinical practice guidelines of Russian gastroenterological association, Scientific society for the clinical study of human microbiome, Russian society for the prevention of non-communicable diseases, Interregional association for clinical microbiology and antimicrobial chemotherapy for H. pylori diagnostics and treatment in adults. Rossiyskiy zhurnal gastroenterologii, gepatologii, koloproktologii = Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2022; 32(6): 72–93 (In Russ.)).


https://doi.org/10.22416/1382-4376-2022-32-6-72-93. EDN: QRQFTQ.


31. Сереброва С.Ю., Карева Е.Н., Кургузова Д.О. с соавт. Место кларитромицина в современных схемах эрадикационной терапии инфекции Helicobacter pylori. Медицинский совет. 2023; 17(8): 68–76. (Serebrova S.Yu., Kareva E.N., Kurguzova D.O. et al. The role of clarithromycin in modern Helicobacter pylori eradication therapy regimens. Meditsinskiy sovet = Medical Council. 2023; 17(8): 68–76 (In Russ.)).


https://doi.org/10.21518/ms2023-128. EDN: UOXGEI.


32. Государственный реестр лекарственных средств Минздрава России. Общая характеристика лекарственного препарата Клацид® СР, 500 мг, таблетки с пролонгированным высвобождением, покрытые пленочной оболочкой. РУ: ЛП-№(004803)-(РГ-RU) от 06.03.2024. Доступ: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=948ce4e2-112b-4971-9549-923c6de42309 (дата обращения – 24.06.2024). (State register of medicines of the Ministry of Healthcare of Russia. General characteristics of the drug Klacid® SR, 500 mg, extended-release, film-coated tablets. Registration certificate: ЛП-№(004803)-(РГ-RU) dated from 03/06/2024. URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=948ce4e2-112b-4971-9549-923c6de42309 (date of access – 24.06.2024) (In Russ.)).


33. Государственный реестр лекарственных средств Минздрава России. Общая характеристика лекарственного препарата Клацид®, 500 мг, таблетки, покрытые пленочной оболочкой. РУ: ЛП-№(001693)-(РГ-RU) от 19.01.2023. Доступ:


https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=ab097640-e2fc-4f06-88b7-5d96b5f1c386 (дата обращения – 24.06.2024). (State register of medicines of the Ministry of Healthcare of Russia. General characteristics of the drug Klacid®, 500 mg, film-coated tablets. Registration certificate: ЛП-№(001693)-(РГ-RU) dated from 01/19/2023. URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=ab097640-e2fc-4f06-88b7-5d96b5f1c386 (date of access – 24.06.2024) (In Russ.)).


About the Autors

Elena V. Luzina, MD, PhD (Medicine), associate professor of the Department of therapy, faculty of additional professional training, Chita State Medical Academy of the Ministry of Healthcare of Russia, chairman of Transbaikal Scientific Society of Gastroenterologists. Address: 672000, Chita, 39A Gorkogo St.
E-mail: el.luz@list.ru
ORCID: https://orcid.org/0000-0002-8282-3056. eLibrary SPIN: 6748-9361
Leonid B. Lazebnik, MD, Dr.Sci. (Medicine), professor, professor of the Department of polyclinic therapy, Russian University of Medicine of the Ministry of Healthcare of Russia, vice-president of the Russian Scientific Medical Society of Internal Medicine (RSMSIM), president of the Scientific Society of Gastroenterologists of Russia, member of the Presidium of the Society of Doctors of Russia, member of the Presidium of National Medical Chamber. Address: 127473, Moscow, 20/1 Delegatskaya St.
E-mail: leonid.borisl@gmail.com
ORCID: https://orcid.org/0000-0001-8736-5851
Natalya V. Lareva, MD, Dr.Sci. (Medicine), professor, vice-rector for scientific and international affairs, head of the Department of therapy of the Faculty of additional professional training, Chita State Medical Academy of the Ministry of Healthcare of Russia, chairman of the Transbaikal regional branch of the Russian Scientific Medical Society of Internal Medicine (RSMSIM). Address: 672000, Chita, 39A Gorkogo St.
E-mail: larevanv@mail.ru
ORCID: https://orcid.org/0000-0001-9498-9216. eLibrary SPIN: 1228-6205
Albina A. Zhilina, MD, Dr.Sci. (Medicine), associate professor, vice-rector for academic affairs, educational activities and youth policy, professor of the Department of therapy of the Faculty of additional professional training, Chita State Medical Academy of the Ministry of Healthcare of Russia. Address: 672000, Chita, 39A Gorkogo St.
E-mail: albina1228@ya.ru
ORCID: https://orcid.org/0000-0002-4405-2975
Aksana A. Moskvitina, MD, gastroenterologist at Multidisciplinary Medical Center “Medlux”. Address: 672039, Chita, 97, room 1, Babushkina St.
E-mail: mosk.oksana@bk.ru
ORCID: https://orcid.org/0009-0002-6346-7487


Similar Articles

Back to Content

Бионика Медиа